LLY·Healthcare·Pharma
Eli Lilly LillyDirect +5.4% as Weight Watchers Expands Access
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy?
Pharma
LLY·Healthcare·Pharma
NVO·Healthcare·Pharma
Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum?
LLY·Healthcare·Pharma
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war?
LLY·Healthcare·Pharma
Eli Lilly Acquisition $3.8B Push Opens Vaccine Growth Lane
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines?
ABBV·Healthcare·Dividend Aristocrats
AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises?
LLY·Healthcare·Pharma
Eli Lilly Earnings +56%: Can the GLP‑1 Boom Last?
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit…
AMGN·Healthcare·Biotech
Amgen Earnings -5.3% Plunge: Guidance Shock Despite Upgrade
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…
NVO·Healthcare·Pharma
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom?
ABBV·Healthcare·Dividend Aristocrats
AbbVie Earnings +4.5% Surge After Bullish Upgrade Shock
Are AbbVie Earnings and a surprise Bank of America upgrade signaling a new phase in the pharma giant’s post-Humira transition?
LLY·Healthcare·Pharma
Eli Lilly Earnings Soar 156% as GLP‑1 Boom Lifts Outlook
Are Eli Lilly earnings finally proving that the GLP‑1 obesity boom can justify today’s sky‑high valuation?